Workflow
达利雷生上市首月美团搜索量激增160%,抗失眠新药加码布局即时零售
2 1 Shi Ji Jing Ji Bao Dao·2025-09-22 14:04

Core Insights - The new insomnia drug, Darilresin, from the company has gained significant attention, with a search volume increase of over 160% in the past two weeks, making it a popular choice in the insomnia treatment market [1] - Sleep health issues are prevalent in China, with nearly half (48.5%) of adults experiencing sleep difficulties, highlighting a substantial market opportunity for insomnia treatments [1] - Darilresin operates as a dual appetite receptor antagonist, improving nighttime sleep quality and daytime functionality without altering sleep structure, thus avoiding the sedation effects common in traditional insomnia medications [1] - The drug is not classified as a controlled substance, lowering the barriers for patient access [1] Company Initiatives - The company has streamlined its drug launch process, reducing the time from 8 months to just over 2 months by directly importing the drug and completing packaging at its Hainan production base, achieving over 60% efficiency improvement [1] - Collaborations with platforms like Meituan Buy Medicine have been established for deep cooperation in the drug's launch, facilitating rapid distribution across multiple cities [1] Market Demand - Major cities such as Shenzhen, Guangzhou, Beijing, Chongqing, and Wuhan are leading in search demand for the drug, with significant nighttime consumption patterns observed, peaking between 19:00 and 24:00 [2] - The platform has introduced two packaging options (7 tablets and 20 tablets) to cater to diverse patient needs, with ongoing efforts to expand coverage to over 100 cities and thousands of 24-hour pharmacies [2] - A sleep clinic has been launched in collaboration with Meituan Buy Medicine, offering online consultations with top-tier doctors, medication guidance, and 24-hour retail services [2]